Diffuse intrinsic pontine glioma (DIPG) is the leading cause of pediatric brain tumor related death. Due to their anatomical location and infiltrative nature, surgery is not feasible, and the current standard care is palliative radiation therapy (RT) alone. This treatment can aid in symptom control and prolong survival; however, it is not curative. DIPG is nearly universally fatal with a median survival of less than one year, and majority of patients succumbing to the disease within two years after diagnosis. Curative therapies with children with DIPG is a critically unmet need in pediatric oncology.